Michelle Gilson
Stock Analyst at Morgan Stanley
(0.41)
# 2,927
Out of 4,424 analysts
12
Total ratings
33.33%
Success rate
-12.1%
Average return
Main Sectors:
Top Industries:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Equal-Weight | $27 → $15 | $9.44 | +58.90% | 2 | Jul 21, 2023 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $27.04 | +10.95% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | n/a | $2.99 | - | 1 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | n/a | $133.46 | - | 2 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | n/a | $6.30 | - | 1 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | n/a | $11.48 | - | 1 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | n/a | $81.03 | - | 4 | Aug 20, 2020 |
Vir Biotechnology
Jul 21, 2023
Maintains: Equal-Weight
Price Target: $27 → $15
Current: $9.44
Upside: +58.90%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $27.04
Upside: +10.95%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: n/a
Current: $2.99
Upside: -
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: n/a
Current: $133.46
Upside: -
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: n/a
Current: $6.30
Upside: -
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: n/a
Current: $11.48
Upside: -
BioMarin Pharmaceutical
Aug 20, 2020
Maintains: Buy
Price Target: n/a
Current: $81.03
Upside: -